Form 4: BridgeBio CAO Sells Shares Under 10b5-1 Plan

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the sale of 510 common shares under a pre-arranged 10b5-1 trading plan, alongside shares withheld for tax obligations.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), reported transactions involving the company's common stock.
• On February 16, 2026, 4,349 shares of common stock were withheld at a price of $75.25 per share to cover tax obligations related to the vesting of 8,377 Restricted Stock Units (RSUs).
• Following this, Apuli beneficially owned 124,455 shares.
• On February 17, 2026, Apuli sold 510 shares of common stock at a price of $74.31 per share.
• This sale was executed under a Rule 10b5-1 trading plan established on September 8, 2025.
• After all reported transactions, Apuli beneficially owns 123,945 shares of BridgeBio Pharma common stock.
• The reported beneficial ownership also includes 510 shares acquired on February 13, 2026, through the company's Employee Stock Purchase Plan (ESPP).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is pre-planned and routine, offsetting the positive of RSU vesting and ESPP acquisition, and does not signal a significant change in company prospects.

Positives

• Vesting of 8,377 Restricted Stock Units (RSUs) indicates compensation and retention of a key executive.
• Acquisition of 510 shares through the Employee Stock Purchase Plan (ESPP) on February 13, 2026, suggests continued employee investment in the company.

Negatives

• The sale of 510 shares by a Chief Accounting Officer, even under a 10b5-1 plan, represents a reduction in insider holdings.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, especially those executed under pre-arranged 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage personal finances and diversify holdings. These transactions typically do not reflect a change in the company's fundamental outlook.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a Chief Accounting Officer, even under a 10b5-1 plan, could be perceived as a minor negative, though the pre-planned nature mitigates concerns. The RSU vesting and ESPP acquisition are generally positive for executive alignment.
• Employees: The RSU vesting and ESPP acquisition highlight ongoing employee compensation and benefit programs.

Key Dates

Recommendation

The filing details routine insider transactions, including tax-related share withholding and a pre-planned sale under a 10b5-1 plan. These actions are typical for executives managing their compensation and personal finances and do not provide new material information about BridgeBio Pharma's operational performance or future prospects that would warrant a change in investment recommendation. The small scale of the sale relative to total holdings further supports a neutral stance.

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Restricted Stock Units, RSU Vesting, Employee Stock Purchase Plan, ESPP, Maricel Apuli, Chief Accounting Officer